GlassScriptPhysician profile
Milan K Patel
NPI 1982885646
$1,017.87
in general payments reported to CMS, 2019-2025
26 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $72.58 · 2021: $43.08 · 2022: $40.89 · 2023: $298 · 2024: $191 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.10 |
| Education | $127.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $145.10 | 2019-2025 | |
| Pfizer INC. | $109.62 | 2019-2025 | |
| Mediview Xr, INC. | $91.95 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $78.00 | 2022-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $72.00 | 2019-2023 | |
| Glaxosmithkline, LLC. | $55.40 | 2022-2025 | Jemperli, Blenrep, Ojjaara |
| Abbvie INC. | $52.02 | 2024-2025 | |
| Okami Medical, INC. | $50.74 | 2024 | Lobo |
| Array Biopharma INC | $39.36 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
| Lexicon Pharmaceuticals, INC. | $32.83 | 2019 | |
| Bard Peripheral Vascular, INC. | $31.16 | 2021 | |
| Merck Sharp & Dohme LLC | $29.91 | 2020-2023 | Welireg, Keytruda, Lynparza |
| Amgen INC. | $20.86 | 2023 | Nplate, Xgeva |
| Myriad Genetic Laboratories, INC. | $20.03 | 2023 | Precisetumor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.74 | 2023 | Xtandi |
| Ipsen Biopharmaceuticals, INC | $17.76 | 2019 | |
| Incyte Corporation | $15.94 | 2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $15.01 | 2025 | Sylvant |
| Karyopharm Therapeutics INC. | $13.83 | 2020 | |
| Janssen Biotech, INC. | $12.65 | 2020 | |
| Dova Pharmaceuticals | $12.59 | 2020 | |
| Acrotech Biopharma INC. | $11.97 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.85 | 2019 | |
| Secura Bio, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.